| Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ... New England Journal of Medicine 377 (20), 1919-1929, 2017 | 4032 | 2017 |
| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ... The Lancet 393 (10183), 1819-1830, 2019 | 2893 | 2019 |
| Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350, 2018 | 2620 | 2018 |
| ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up N Colombo, C Creutzberg, F Amant, T Bosse, A González-Martín, ... International Journal of Gynecologic Cancer 26 (1), 2016 | 1890 | 2016 |
| Pembrolizumab for persistent, recurrent, or metastatic cervical cancer N Colombo, C Dubot, D Lorusso, MV Caceres, K Hasegawa, ... New England Journal of Medicine 385 (20), 1856-1867, 2021 | 561 | 2021 |
| Lenvatinib plus pembrolizumab for advanced endometrial cancer V Makker, N Colombo, A Casado Herráez, AD Santin, E Colomba, ... New England Journal of Medicine 386 (5), 437-448, 2022 | 471 | 2022 |
| ESMO-ESGO-ESTRO endometrial consensus conference working group N Colombo, C Creutzberg, F Amant, T Bosse, A Gonzalez-Martin, ... ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis …, 2016 | 315 | 2016 |
| Perianal infections in patients with leukemia: importance of the course of neutrophil count Y Büyükaşık, OI Özcebe, N Sayınalp, IC Haznedaroğlu, ÖÖ Altundağ, ... Diseases of the colon & rectum 41, 81-85, 1998 | 85 | 1998 |
| Induction chemotherapy with cisplatin and 5‐fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of … O Altundag, I Gullu, K Altundag, S Yalcin, E Ozyar, M Cengiz, F Akyol, ... Head & neck 27 (1), 15-21, 2005 | 63 | 2005 |
| Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study T Guvenal, P Dursun, PS Hasdemir, M Hanhan, S Guven, H Yetimalar, ... Gynecologic oncology 131 (3), 546-550, 2013 | 56 | 2013 |
| Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy O Altundag, DJ Stewart, FV Fossella, GD Ayers, W Wei, X Zhou, ... Journal of Thoracic Oncology 2 (2), 141-146, 2007 | 55 | 2007 |
| Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma O Altundag, K Altundag, E Gunduz Journal of clinical oncology 23 (5), 2005 | 55 | 2005 |
| The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer A Ayhan, E Günakan, İ Alyazıcı, N Haberal, Ö Altundağ, P Dursun Archives of Gynecology and Obstetrics 296, 989-995, 2017 | 48 | 2017 |
| A Turkish Gynecologic Oncology Group study of fertility‐sparing treatment for early‐stage endometrial cancer P Dursun, S Erkanli, AB Güzel, M Gultekin, NC Tarhan, O Altundag, ... International Journal of Gynecology & Obstetrics 119 (3), 270-273, 2012 | 42 | 2012 |
| Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: the Baskent University experience F Kose, A Besen, T Sumbul, A Sezer, C Karadeniz, U Disel, O Altundag, ... Asian Pac J Cancer Prev 12 (5), 1185-1188, 2011 | 31 | 2011 |
| Addition of granulocyte-colony stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant … K Altundag, O Altundag, ET Elkiran, M Cengiz, Y Ozisik Medical hypotheses 63 (1), 56-58, 2004 | 31 | 2004 |
| Management of Kikuchi-Fujimoto disease using glucocorticoid: a case report S Yalcin, SK Toprak, B Erismis, O Altundag, H Ozdemir, N Topcuoglu Case reports in medicine 2011, 2011 | 30 | 2011 |
| DNA methylation inhibitor, procainamide, may decrease the tamoxifen resistance by inducing overexpression of the estrogen receptor beta in breast cancer patients O Altundag, K Altundag, M Gunduz Medical hypotheses 63 (4), 684-687, 2004 | 30 | 2004 |
| The relationship between glucose metabolism disorders and malignant thyroid disease AO Duran, C Anil, A Gursoy, A Nar, O Altundag, NB Tutuncu International journal of clinical oncology 18, 585-589, 2013 | 26 | 2013 |
| Possible association between nanobacteria and malignant microcalcifications in breast cancer K Altundag, O Altundag, S Akyurek, MA Atik Breast J 12 (3), 287, 2006 | 26 | 2006 |
